NCT05725070View on ClinicalTrials.gov

Phase 0/1 Study of 212Pb-NG001 in mCRPC

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

March 6, 2023

Primary Completion Date

July 6, 2023

Study Completion Date

July 6, 2023

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

212Pb-NG001

"212Pb-NG001 is a targeted alpha-emitting radiopharmaceutical conjugated to a PSMA targeting peptide.~Patients will receive an initial single 10 MBq dose IV to explore the imaging potential of 212Pb-NG001."

Trial Locations (1)

Unknown

Oslo University Hospital, Oslo

Sponsors

Lead Sponsor

ARTBIO Inc.
All Listed Sponsors
lead

ARTBIO Inc.

INDUSTRY

NCT05725070 - Phase 0/1 Study of 212Pb-NG001 in mCRPC | Biotech Hunter | Biotech Hunter